newsfilter
← Latest News
GlobeNewswire·

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for